QRG Capital Management Inc. Has $34.66 Million Position in Stryker Co. (NYSE:SYK)

QRG Capital Management Inc. boosted its position in shares of Stryker Co. (NYSE:SYK) by 57.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 96,251 shares of the medical technology company’s stock after purchasing an additional 35,002 shares during the quarter. QRG Capital Management Inc.’s holdings in Stryker were worth $34,655,000 as of its most recent SEC filing.

A number of other institutional investors have also recently bought and sold shares of the company. Alecta Tjanstepension Omsesidigt bought a new position in Stryker in the fourth quarter valued at approximately $63,556,000. Proficio Capital Partners LLC lifted its stake in Stryker by 52,520.8% in the fourth quarter. Proficio Capital Partners LLC now owns 596,194 shares of the medical technology company’s stock valued at $214,660,000 after buying an additional 595,061 shares in the last quarter. Kovack Advisors Inc. lifted its stake in Stryker by 8.7% in the fourth quarter. Kovack Advisors Inc. now owns 726 shares of the medical technology company’s stock valued at $261,000 after buying an additional 58 shares in the last quarter. FUKOKU MUTUAL LIFE INSURANCE Co lifted its stake in Stryker by 23.2% in the fourth quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,721 shares of the medical technology company’s stock valued at $620,000 after buying an additional 324 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. lifted its stake in Stryker by 2.3% in the fourth quarter. Mn Services Vermogensbeheer B.V. now owns 135,100 shares of the medical technology company’s stock valued at $48,643,000 after buying an additional 3,100 shares in the last quarter. Institutional investors and hedge funds own 77.09% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts have weighed in on the stock. Argus set a $450.00 price target on shares of Stryker in a research note on Monday, February 3rd. JMP Securities reaffirmed a “market perform” rating on shares of Stryker in a research note on Tuesday, February 18th. Canaccord Genuity Group boosted their price objective on shares of Stryker from $420.00 to $435.00 and gave the stock a “buy” rating in a research report on Wednesday, January 29th. Royal Bank of Canada boosted their price objective on shares of Stryker from $425.00 to $435.00 and gave the stock an “outperform” rating in a research report on Wednesday, January 29th. Finally, Evercore ISI boosted their price objective on shares of Stryker from $380.00 to $384.00 and gave the stock an “outperform” rating in a research report on Wednesday, October 30th. Five equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $422.15.

Stryker Price Performance

NYSE:SYK opened at $391.54 on Thursday. Stryker Co. has a one year low of $314.93 and a one year high of $406.19. The company has a market cap of $149.40 billion, a P/E ratio of 50.46, a P/E/G ratio of 2.93 and a beta of 0.96. The firm’s fifty day moving average price is $379.42 and its two-hundred day moving average price is $370.37. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.95 and a quick ratio of 1.32.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, January 28th. The medical technology company reported $4.01 EPS for the quarter, beating the consensus estimate of $3.87 by $0.14. Stryker had a net margin of 13.25% and a return on equity of 23.58%. During the same period in the prior year, the company earned $3.46 EPS. Equities analysts expect that Stryker Co. will post 13.47 earnings per share for the current year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Investors of record on Monday, March 31st will be paid a $0.84 dividend. The ex-dividend date is Monday, March 31st. This represents a $3.36 annualized dividend and a dividend yield of 0.86%. Stryker’s dividend payout ratio (DPR) is presently 43.30%.

Insider Activity at Stryker

In related news, Director Allan C. Golston sold 2,458 shares of the company’s stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $383.07, for a total value of $941,586.06. Following the transaction, the director now directly owns 14,895 shares in the company, valued at approximately $5,705,827.65. This represents a 14.16 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Ronda E. Stryker sold 201,392 shares of the company’s stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $392.24, for a total transaction of $78,993,998.08. Following the completion of the transaction, the director now owns 3,642,075 shares in the company, valued at $1,428,567,498. This trade represents a 5.24 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 5.90% of the stock is currently owned by corporate insiders.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.